Received Feb 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | 3L339 | — |
administer to 60 year old patient"; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 60-year-old male patient who received Men B NVS (Bexsero) (batch number 3L339, expiry date 03-SEP-2027) for prophylaxis. On 11-FEB-2025, the patient received the 1st dose of Bexsero. On 11-FEB-2025, an unknown time after receiving Bexsero, the patient experienced inappropriate age at vaccine administration (Verbatim: administer to 60 year old patient"). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-FEB-2025 The reporter reported that there was a vaccine, the Bexsero vaccine that it was administered at our pharmacy on 11th February 2025, it said that the ages was between 10 to 25 years of age for administration, and the pharmacist that worked that day did not see that and administer to 60 year old patient. The Vaccine Administration Facility was the same as Primary Reporter. The healthcare professional mentioned that this was the 1st Bexsero dose that the patient received which led to inappropriate age at vaccine administration.